Metaphase arrest and cell death induced by etoposide on HeLa cells

International Journal of Biochemistry and Cell Biology

Volumn 38, Issue 12, 2006, Pages 2183-2195

  Rello Varona, Santiago ^a   Gámez, Angelo ^a   Moreno, Vanessa ^a   Stockert, Juan Carlos ^a   Cristóbal, Javier ^a   Pacheco, María ^a   Cañete, Magdalena ^a   Juarranz, Ángeles ^a   Villanueva, Ángeles ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Apoptosis; Etoposide; HeLa cells; Metaphase arrest; Mitotic catastrophe

Indexed keywords

ETOPOSIDE;

APOPTOSIS; ARTICLE; CELL DEATH; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; HELA CELL; HUMAN; HUMAN CELL; INCUBATION TIME; INTERPHASE; METAPHASE; MITOSIS; POLYPLOIDY;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL DEATH; CELL SURVIVAL; ETOPOSIDE; FLOW CYTOMETRY; HELA CELLS; HUMANS; METAPHASE; MICROSCOPY, ELECTRON, SCANNING; MITOTIC SPINDLE APPARATUS; POLYPLOIDY;

EID: 33748688799     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2006.06.013     Document Type: Article

References (60)

1. Andoh T., and Ishida R. Catalytic inhibitors of DNA topoisomerase II. Biochimica et Biophysica Acta 1400 (1998) 155-171
2. Andreassen P.R., Lacroix F.B., Lohez O.D., and Margolis R.L. Neither p21WAF1 nor 14-3-3sigma prevents G2 progression to mitotic catastrophe in human colon carcinoma cells after DNA damage, but p21WAF1 induces stable G1 arrest in resulting tetraploid cells. Cancer Research 61 (2001) 7660-7668
3. Ayene I.S., Ford L.P., and Koch C.J. Ku protein targeting by Ku70 small interfering RNA enhances human cancer cell response to topoisomerase II inhibitor and gamma radiation. Molecular Cancer Therapeutics 4 (2005) 529-536
4. Bartling B., Lewensohn R., and Zhivotovsky B. Endogenously released Smac is insufficient to mediate cell death of human lung carcinoma in response to etoposide. Experimental Cell Research 298 (2004) 83-95
5. Bartova E., Jirsova P., Fojtova M., Soucek K., and Kozubek S. Chromosomal territory segmentation in apoptotic cells. Cellular and Molecular Life Sciences 60 (2003) 979-990
6. Blass M., Kronfeld I., Kazimirsky G., Blumberg P.M., and Brodie C. Tyrosine phosphorylation of protein kinase Cdelta is essential for its apoptotic effect in response to etoposide. Molecular and Cellular Biology 22 (2002) 182-195
7. Boldt S., Weidle U.H., and Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 23 (2002) 1831-1838
8. Brown J.M., and Wouters B.G. Apoptosis, p53, and tumor cell sensitivity to anticancer agents. Cancer Research 59 (1999) 1391-1399
9. Clifford B., Beljin M., Stark G.R., and Taylor W.R. G2 arrest in response to topoisomerase II inhibitors: The role of p53. Cancer Research 63 (2003) 4074-4081
10. Coon J.S., Marcus E., Gupta-Burt S., Seelig S., Jacobson K., Chen S., Renta V., Fronda G., and Preisler H.D. Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clinical Cancer Research 8 (2002) 1061-1067
11. Elliott M.J., Stribinskiene L., and Lock R.B. Expression of Bcl-2 in human epithelial tumor (HeLa) cells enhances clonogenic survival following exposure to 5-fluoro-2′-deoxyuridine or staurosporine, but not following exposure to etoposide or doxorubicin. Cancer Chemotherapy and Pharmacology 41 (1998) 457-463
12. Erenpreisa J.E., and Cragg M.S. Mitotic death: A mechanism of survival? A review. Cancer Cell International 1 (2001) 1
13. Erenpreisa J.E., Ivanov A., Dekena G., Vitina A., Krampe R., Freivalds T., Selianova G., and Roach H.I. Arrest in metaphase and anatomy of mitotic catastrophe: Mild heat shock in two human osteosarcoma cell lines. Cell Biology International 24 (2000) 61-70
14. Evan G.I., and Vousden K.H. Proliferation, cell cycle and apoptosis in cancer. Nature 411 (2001) 342-348
15. Facompre M., Wattez N., Kluza J., Lansiaux A., and Bailly C. Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide. Molecular Cell Biology Research Communications 4 (2000) 37-42
16. Fleischer A., and Rebollo A. Induction of p53-independent apoptosis by the BH3-only protein ITM2Bs. FEBS Letters 557 (2004) 283-287
17. Fletcher L., Yen T.J., and Muschel R.J. DNA damage in HeLa cells induced arrest at a discrete point in G2 phase as defined by CENP-F localization. Radiation Research 159 (2003) 604-611
18. Fortune J.M., and Osheroff N. Topoisomerase II as a target for anticancer drugs: When enzymes stop being nice. Progress in Nucleic Acid Research and Molecular Biology 64 (2000) 221-253
19. Gerl R., and Vaux D.L. Apoptosis in the development and treatment of cancer. Carcinogenesis 26 (2005) 263-270
20. Godard T., Deslandes E., Sichel F., Poul J.M., and Gauduchon P. Detection of topoisomerase inhibitor-induced DNA strand breaks and apoptosis by the alkaline comet assay. Mutation Research 520 (2002) 47-56
21. Hande K.R. Etoposide: Four decades of development of a topoisomerase II inhibitor. European Journal of Cancer 34 (1998) 1514-1521
22. Hyzy M., Bozko P., Konopa J., and Skladanowski A. Related antitumour imidazoacridone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochemical Pharmacology 69 (2005) 801-809
23. Isaacs R.J., Davies S.L., Sandri M.I., Redwood C., Wells N.J., and Hickson I.D. Physiological regulation of eukaryotic topoisomerase II. Biochimica et Biophysica Acta 1400 (1998) 121-137
24. Jiang H., Luo S., and Li H. Cdk5 activator-binding protein C53 regulates apoptosis induced by genotoxic stress via modulating the G2/M DNA damage checkpoint. The Journal of Biological Chemistry 280 (2005) 20651-20659
25. Johnstone R., Ruefli A., and Lowe S. Apoptosis: A link between cancer genetics and chemotherapy. Cell 108 (2002) 153-164
26. Jordan M.A., Wendell K., Gardiner S., Derry W.B., Copp H., and Wilson L. Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Research 56 (1996) 816-825
27. Kamesaki S., Kamesaki H., Jorgensen T.J., Tanizawa A., Pommier Y., and Cossman J. Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Research 53 (1993) 4251-4256
28. Karpinich N.O., Tafani M., Schneider T., Russo M.A., and Farber J.L. The course of etoposide-induced apoptosis in Jurkat cells lacking p53 and Bax. Journal of Cellular Physiology 208 (2006) 55-63
29. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316-323
30. Kaufmann S.H. Cell death induced by topoisomerase-targeted drugs: More questions than answers. Biochimica et Biophysica Acta 1400 (1998) 195-211
31. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 103 (2005) 1551-1560
32. Kim Y., Koo K.T., Choi J.S., Jin Y.H., Yim H., Oh Y.T., and Lee S.K. Analysis of cyclin-dependent kinase 2-regulated phosphorylation of stathmin in etoposide-induced apoptotic HeLa cells by two-dimensional electrophoresis and mass spectrometry. Journal of Health Science 51 (2005) 224-232
33. Kropotov A.V., Grudinkin P.S., Pleskach N.M., Gavrilov B.A., Tomilin N.V., and Zhivotovsky B. Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Letters 572 (2004) 75-79
34. Larsen A.K., Escargueil A.E., and Skladanowski A. Catalytic topoisomerase II inhibitors in cancer therapy. Pharmacology and Therapeutics 99 (2003) 167-181
35. Larsen A.K., Escargueil A.E., and Skladanowski A. From DNA damage to G2 arrest: The many roles of topoisomerase II. Progress in Cell Cycle Research 5 (2003) 295-300
36. Law J.C., Ritke M.K., Yalowich J.C., Leder G.H., and Ferrell R.E. Mutational inactivation of the p53 gene in the human erythroid leukemic K562 cell line. Leukemia research 17 (1993) 1045-1050
37. Makin G., and Dive C. Apoptosis and cancer chemotherapy. Trends in Cell Biology 11 (2001) S22-S26
38. Makin G., and Dive C. Recent advances in understanding apoptosis: New therapeutic opportunities in cancer chemotherapy. Trends in Molecular Medicine 9 (2003) 251-255
39. Martins L.M., Mesner P.W., Kottke T.J., Basi G.S., Sinha S., Tung J.S., Svingen P.A., Madden B.J., Takahashi A., McCormick D.J., Earnshaw W.C., and Kaufmann S.H. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood 90 (1997) 4283-4296
40. McGahon A., Bissonnette R., Schmitt m., Cotter K.M., Green D.R., and Cotter T.G. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83 (1994) 1179-1187
41. McGahon A.J., Brown D.G., Martin S.J., Amarante-Mendes G.P., Cotter T.G., Cohen G.M., and Green D.R. Downregulation of Bcr-Abl in K562 cells restores susceptibility to apoptosis: Characterization of the apoptotic death. Cell Death and Differentiation 4 (1997) 95-104
42. Meresse P., Dechaux E., Monneret C., and Bertounesque E. Etoposide: Discovery and medicinal chemistry. Current Medicinal Chemistry 11 (2004) 2443-2446
43. Okada H., and Mak T.W. Pathways of apoptotic and non-apoptotic death in tumour cells. Nature Reviews Cancer 4 (2004) 592-603
44. Pommier Y., Sordet O., Antony S., Hayward R.L., and Kohn K.W. Apoptosis defects and chemotherapy resistance: Molecular interaction maps and networks. Oncogene 23 (2004) 2934-2949
45. Potter A.J., and Rabinovitch P.S. The cell cycle phases of DNA damage and repair initiated by topoisomerase II-targeting chemotherapeutic drugs. Mutation Research 572 (2005) 27-44
46. Prokocimer M., Shaklai M., Ben Bassat H., Wolf D., Goldfinger N., and Rotter V. Expression of p53 in human leukemia and lymphoma. Blood 68 (1986) 113-118
47. Qiu L., Burgess A., Fairlie D.P., Leonard H., Parsons P.G., and Gabrielli B.G. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Molecular Biology of the Cell 11 (2000) 2069-2083
48. Rello S., Stockert J.C., Moreno V., Gámez A., Pacheco M., Juarranz A., Cañete M., and Villanueva A. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 10 (2005) 201-208
49. Ridd K., Alexander D.J., and Reed C.J. Foetal rat lung epithelial (FRLE) cells: Alterations in cellular homeostasis and gene expression in response to etoposide, hydrogen peroxide and sodium butyrate. Toxicology 195 (2004) 209-220
50. Robertson J.D., Enoksson M., Suomela M., Zhivotovsky B., and Orrenius S. Caspase-2 acts upstream of mitochondria to promote cytochrome c release during etoposide-induced apoptosis. The Journal of Biological Chemistry 277 (2002) 29803-29809
51. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., and Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63 (1990) 1129-1136
52. Singh S.V., Herman-Antosiewicz A., Singh A.V., Lew K.L., Srivastava S.K., Kamath R., Brown K.D., Zhang L., and Baskaran R. Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle 25C. The Journal of Biological Chemistry 279 (2004) 25813-25822
53. Skoufias D.A., Lacroix F.B., Andreassen P.R., Wilson L., and Margolis R.L. Inhibition of DNA decatenation, but not DNA damage, arrests cells at metaphase. Molecular Cell 15 (2004) 977-990
54. Sleiman R.J., and Stewart B.W. Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: Evidence of commitment to apoptosis rather than mitotic cell death. Clinical Cancer Research 6 (2000) 3756-3765
55. Sun Y. p53 and its downstream proteins as molecular targets of cancer. Molecular Carcinogenesis 45 (2006) 409-415
56. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., and Haga N. Molecular targeting therapy of cancer: Drug resistance, apoptosis and survival signal. Cancer Science 94 (2003) 15-21
57. Vousden K.H. Activation of the p53 tumor suppressor protein. Biochimica et Biophysica Acta 1602 (2002) 47-59
58. Wang H., Mao Y., Zhou N., Hu T., Hsieh T.S., and Liu L.F. ATP-bound topoisomerase II as a target for antitumor drugs. The Journal of Biological Chemistry 276 (2001) 15990-15995
59. Wilstermann A.M., and Osheroff N. Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes. Current Topics in Medicinal Chemistry 3 (2003) 321-338
60. Woessner R.D., Mattern M.R., Mirabelli C.K., Johnson R.K., and Drake F.H. Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth and Differentiation 2 (1991) 209-214